You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Vantage Biosciences launched to take on diabetic eye disease

Vantage Biosciences, a new company that focuses on novel therapeutics, has announced the acquisition of VX-01, an oral therapy targeting diabetic eye diseases.